Scarica l'app Stockscreener
22.59
0.22%
0.05
Uniqure Nv Borsa (QURE) Ultime notizie
Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE) - Simply Wall Street
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 37.3% Share Drop - Business Wire
uniQure N.V. (QURE) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
UniQure Shares Fall After Barclays Downgrade - marketscreener.com
Barclays Downgrades UniQure to Equal Weight From Overweight - Moomoo
Uniqure N.v Stock Price Forecast. Should You Buy QURE? - StockInvest.us
Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy - STAT
$uniQure NV (QURE.US)$ - Moomoo
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights - GlobeNewswire Inc.
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update - Seeking Alpha
uniQure Plunges on Additional Data From Huntington's Disease Study - Zacks Investment Research
uniQure Plunges on Additional Data From Huntington's Disease Study - Yahoo Finance
uniQure Stock Plunges On 4-Year Data, But The Approval Path Is Intact (Rating Upgrade) - Seeking Alpha
EBITDA of uniQure N.V. – HAN:UQ1 - TradingView
Return on invested capital % of uniQure N.V. – HAN:UQ1 - TradingView
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - Morningstar
Four-year data raise durability questions for uniQure’s Huntington gene therapy - biocentury.com
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - PR Newswire
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE) - The Transylvania Times
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish (QURE) - Seeking Alpha
uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease Highlighting Disease Progression SlowingSlideshow (NASDAQ:QURE) 2026-09-29 - Seeking Alpha
QURE Investor Alert: uniQure Securities InvestigationKehoe Law Firm, P.C. - GlobeNewswire Inc.
Why Is uniQure Stock Sinking on Tuesday? - benzinga.com
Why Is uniQure Stock Sinking on Tuesday? - Yahoo Finance
uniQure Highlights Long-Term AMT-130 Huntington’s Data - TipRanks
uniQure Shares Fall 64% After 48-Month AMT-130 Huntington’s Disease Trial Update - finance.yahoo.com
ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update - finance.yahoo.com
uniQure: 80% Slowing on Huntington's Score at 3 Years - Stock Titan
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data – Here’s What Investors Need To Know - finance.yahoo.com
uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat - finance.yahoo.com
uniQure posts new data for Huntington’s disease drug (QURE) - Seeking Alpha
Why is uniQure stock collapsing today? - Investing.com
uniQure Announces Additional Data from Ongoing Phase I/II - globenewswire.com
UniQure’s gene therapy continues to slow Huntington’s progression after four years - STAT
UniQure Sinks After Worse-Than-Expected Huntington’s Results - Bloomberg.com
uniQure (NasdaqGS:QURE) Stock Forecast & Analyst Predictions - Simply Wall Street
uniQure stock falls 10.38 percent as cash reaches USD 810.3 million - AD HOC NEWS
Why is uniQure stock sliding today? - Investing.com
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With A 56% Upside Potential - DirectorsTalk Interviews
What to expect from UniQure’s upcoming Huntington’s gene therapy readout - STAT
uniQure (QURE) Submitted AMT-130 for Accelerated Approval in Huntington’s Disease. Can Externally Controlled Data Support the Application? - Yahoo Finance
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players - NeurologyLive
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
QURE stock gains as uniQure moves closer to FDA review for Huntington’s gene therapy - AD HOC NEWS
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
uniQure (QURE) Stock Could Be Fully Valued As It Files For AMT 130 Approval - Yahoo Finance
1.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):